Business
Samsung Biologics PolyPeptide acquisition focus: $1.8B
Samsung Biologics has agreed to acquire PolyPeptide Group AG, a Swiss contract drugmaker, in an all-cash deal valued at about 1.46 billion Swiss francs…
Samsung Biologics has agreed to acquire PolyPeptide Group AG, a Swiss contract drugmaker, in an all-cash deal valued at about 1.46 billion Swiss francs…